<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0272170" disease_type="Disease or Syndrome" abbrv="">Shwachman-Diamond syndrome</z:e> (<z:chebi fb="26" ids="8984">SDS</z:chebi>) is an <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo> disorder characterized by <z:e sem="disease" ids="C0030293" disease_type="Disease or Syndrome" abbrv="">pancreatic insufficiency</z:e> and variable degrees of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="26" ids="8984">SDS</z:chebi> patients are at risk of developing <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, and leukemic transformation </plain></SENT>
<SENT sid="2" pm="."><plain>The role and timing of allogeneic hematopoietic stem cell transplantation (HSCT) in <z:chebi fb="26" ids="8984">SDS</z:chebi> remain controversial </plain></SENT>
<SENT sid="3" pm="."><plain>We report three <z:chebi fb="26" ids="8984">SDS</z:chebi> patients with severe <z:mpath ids='MPATH_58'>aplasia</z:mpath> transplanted using unrelated umbilical cord blood (UCB) </plain></SENT>
<SENT sid="4" pm="."><plain>Patients received melphalan (180 mg/m2), <z:chebi fb="0" ids="4911">etoposide</z:chebi> (1200 mg/m2), anti-thymocyte globulin (90 mg/kg), and total lymphoid irradiation (500 cGy); <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) prophylaxis consisted of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and <z:chebi fb="0" ids="8382">prednisone</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Myeloid engraftment occurred promptly with absolute neutrophil count &gt;500 cells/mm3 on day 15 +/- 5 and <z:hpo ids='HP_0000001'>all</z:hpo> patients displayed 100% donor chimerism by 2 months post transplant </plain></SENT>
<SENT sid="6" pm="."><plain>The major complication of transplant was GVHD, with <z:hpo ids='HP_0000001'>all</z:hpo> patients developing grade II or III <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD, one progressing to <z:hpo ids='HP_0011010'>chronic</z:hpo> extensive GVHD </plain></SENT>
<SENT sid="7" pm="."><plain>Patients are alive 309, 623, and 2029 days post transplant </plain></SENT>
<SENT sid="8" pm="."><plain>Factors important in HSCT outcome for <z:chebi fb="26" ids="8984">SDS</z:chebi> may include transplantation at a young age, avoidance of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, and adequate GVHD prophylaxis </plain></SENT>
<SENT sid="9" pm="."><plain>Importantly, these cases also suggest that unrelated UCB, in the absence of a matched family member, is an excellent alternative stem cell source for <z:chebi fb="26" ids="8984">SDS</z:chebi> patients undergoing HSCT </plain></SENT>
</text></document>